The Drug Regulatory Authority of Pakistan (DRAP) has announced the immediate recall of several batches of Famila 28F contraceptive tablets after routine testing identified significant quality control failures. The affected batches were flagged for content uniformity issues in the hormones Levonorgestrel and Ethinyl Estradiol, as well as iron content variability, which may compromise contraceptive effectiveness and lead to inconsistent iron supplementation.

DRAP has directed all pharmacists, chemists, and healthcare professionals to stop distributing these batches immediately, quarantine existing stock, and return them to suppliers. Authorities have ramped up market surveillance and regulatory enforcement to ensure the complete removal of these products from circulation.

Patients and consumers who may have used the affected tablets are advised to consult a healthcare provider immediately. Healthcare facilities and professionals are also being asked to report any suspected adverse effects through DRAP’s pharmacovigilance channels.

This recall reinforces DRAP’s commitment to upholding medicine safety and quality standards nationwide. It underscores the importance of regular industry audits and ensures that only products meeting stringent specifications remain available to the public.